Iida S, Kakudo S, Mori Y, Matsui M, Magota K, Kitajima Y, Nakamura N, Mano H, Hakeda Y, Azuma H, Kurokawa T, Kumegawa M
Department of Orthopedic Surgery, Saitama Medical School, Moroyama, Saitama 350-04.
Calcif Tissue Int. 1996 Aug;59(2):100-4. doi: 10.1007/s002239900094.
Human calcitonin (hCT) has been reported to have a less hypocalcemizing effect on rats and to have a lower binding affinity for the receptor of mouse osteoclasts than salmon CT(sCT). In this study we comparatively examined the effect of hCT and sCT on osteoclastic bone-resorbing activity of unfractionated cells obtained from human giant cell tumor of bone and from rabbit and mouse long bones. We found that hCT had the same inhibitory effect as sCT on the bone-resorbing activity of human and rabbit osteoclastic cells, but a different one on that of mouse cells. These results indicate that the activity of drugs should be assayed using human cells if possible.
据报道，人降钙素（hCT）对大鼠的降钙作用较弱，且与鲑鱼降钙素（sCT）相比，对小鼠破骨细胞受体的结合亲和力较低。在本研究中，我们比较研究了hCT和sCT对从人骨巨细胞瘤以及兔和小鼠长骨中获取的未分级细胞的破骨细胞骨吸收活性的影响。我们发现，hCT对人和兔破骨细胞的骨吸收活性具有与sCT相同的抑制作用，但对小鼠破骨细胞的骨吸收活性的抑制作用不同。这些结果表明，如有可能，应使用人类细胞来测定药物的活性。
